Developer docs
API playgroundTry for free, no card

Search company profiles

L7 Informatics

Full company profile

uuid00008gp

Namestring
L7 Informatics
Legal namestring
L7 Informatics, Inc.
Company typeenum
Private
Founded yearint
2012
Descriptiontext

L7 Informatics is a private life sciences software company founded in 2011 and headquartered in Austin, Texas, with 101-250 employees and $38 million in disclosed funding. It builds and sells L7|ESP, a unified digital platform that orchestrates end-to-end scientific and manufacturing workflows across research, development, manufacturing, and quality in GxP-regulated environments. The platform is built on an ontology-driven knowledge graph that contextualizes data at the point of execution, capturing full relationships between samples, materials, instruments, personnel, and outcomes rather than producing flat records. Built-in applications include L7 LIMS, L7 Notebooks (ELN), L7 MES, and L7 Scheduling, with adjacent modules for inventory, equipment management, stability, biorepository, and location management. Component modules include L7|MASTER (low-code authoring), L7|HUB (FAIR content repository with instrument connectors), L7|INTELLIGENCE (BI/analytics export to Snowflake, Tableau, Power BI), L7|SYNAPSE (agentic AI layer launched April 2026), and L7|EXCHANGE (multi-party orchestration, planned 2027).

The company operates an enterprise SaaS business model with subscription licensing on annual billing cycles, deployable via cloud, on-premises, or hybrid configurations. Pricing is quote-based and not publicly disclosed, sold through direct enterprise field sales augmented by strategic/implementation, technology, and OEM/reseller partners. Customer segments are primarily enterprise and include pharmaceutical companies, biotechs (particularly advanced therapeutics and cell/gene therapy), CDMOs, diagnostics organizations, CROs, academic and cancer research institutions, ag-bio companies, and life science tools providers. Named customers include QIAGEN, Dana-Farber Cancer Institute, The Jackson Laboratory, Cellipont Bioservices, CTMC, Cellares, GeneDx, Cibus, Alpine Bio, Gradalis, and CSI-Dx. Strategic priorities include the agentic AI layer, multi-party orchestration, and the Leica Biosystems pathology partnership (announced November 2025, commercial early 2026).

Short descriptiontext

L7 Informatics builds L7|ESP, an ontology-driven unified platform that orchestrates workflows and contextualizes data across research, development, manufacturing, and quality for regulated pharmaceutical, biotech, CDMO, diagnostics, and research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
laboratory informatics software, workflow orchestration software, GxP compliance software, scientific data management, manufacturing execution systems
Industry4 codes
PRIMARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAI
Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Software Publishers5132
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Integrated Systems Design7373
Product category
Life Sciences Workflow Orchestration Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Software Platform Subscription
TypeSubscription Recurring
Description

L7 Informatics generates revenue primarily through licensing and subscription fees for its L7|ESP unified platform and associated applications (L7 LIMS, L7 MES, L7 Notebooks, L7 Scheduling). The platform is offered via cloud, on-premises, or hybrid deployment models, suggesting a recurring subscription revenue structure. Professional services for implementation, compliance, support, and training further complement the revenue model.

l7informatics.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise subscription licensing with cloud, on-premises, or hybrid deployment options
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing not publicly disclosed; offered via enterprise sales with flexible deployment options to meet diverse operational needs of regulated life sciences organizations.

l7informatics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 11 records shown
1L7|ESP
Description

The Enterprise Science Platform - a unified digital platform that contextualizes data at the point of execution and orchestrates workflows across research, development, manufacturing, and quality for regulated life sciences.

l7informatics.com
+10 more records
Core offering1 text field

L7 Informatics develops and sells L7|ESP (Enterprise Science Platform), a unified digital platform for regulated life sciences that contextualizes data at the point of execution and orchestrates end-to-end scientific and manufacturing workflows across research, development, manufacturing, and quality. The platform is built on an ontology-driven knowledge graph and includes built-in LIMS, ELN, MES, and Scheduling applications, with optional deployment via cloud, on-premises, or hybrid models to meet GxP compliance requirements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Customer-reported efficiency gains of up to 80% after replacing manual or siloed processes with L7|ESP
+3 more records
Product overview1 text field

L7 Informatics offers L7|ESP®, a unified digital platform architecture for regulated life sciences that combines a core execution layer with modular components and best-of-breed applications. The platform components include L7|MASTER® for data and process modeling, L7|HUB® for content repository and FAIR data management, L7|INTELLIGENCE® for data intelligence and export to BI tools, L7|SYNAPSE™ for agentic AI capabilities, and L7|EXCHANGE™ for multi-party orchestration (estimated 2027 release). Built-in applications include L7 LIMS, L7 MES, L7 Notebooks (ELN), L7 Scheduling, L7 Inventory, L7 EM, L7 Stability, L7 Biorepository, and L7 Location—all integrated within the unified platform with workflow orchestration, ontology-driven data contextualization, and AI-actionable data.

Product and service1 record
1L7|ESP® (Enterprise Science Platform)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-29
Description

Leica Biosystems and L7 Informatics formed a strategic partnership to develop an AI-ready pathology platform integrating L7 Informatics' Enterprise Science Platform (L7|ESP) with Leica Biosystems' instrumentation. The collaboration addresses operational challenges in pathology laboratories including siloed data systems, rising diagnostic demands, and workforce shortages. Commercial product availability expected in early 2026. The unified platform is designed to automate workflows and enable AI-driven decision support across the entire pathology workflow from biopsy to diagnosis.

2Strategic and Implementation Partners
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

L7 Informatics partners with strategic and implementation partners to help customers achieve full potential and ensure positive outcomes. These partners provide services including operations assessment, data + process architecture, implementation, compliance, and support, helping businesses achieve full potential and ensure positive outcomes with L7 ESP.

l7informatics.com
3OEM and Reseller Partners
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

OEM partners leverage the power of L7 ESP to bring new digital infrastructure to their customers that unlocks the power of true data intelligence. Reseller partners extend L7's reach to new customer segments.

l7informatics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

BIOVIA provides a broad scientific platform covering lab informatics, ELN, LIMS, and molecular modeling for regulated life sciences. Its enterprise breadth and global install base position it as a broad incumbent competing with L7 ESP across multiple workflow areas.

TypeDirect peer
Description

Benchling is a cloud-native biotech R&D platform offering LIMS, ELN, and workflow orchestration for life sciences R&D. It competes most directly with L7's LIMS, ELN (Notebooks), and unified platform vision for biotech and pharma customers, with overlap in cell/gene therapy and biologics workflows.

TypeDirect peer
Description

Dotmatics provides a scientific R&D informatics platform (LIMS, ELN, data management, decision support) for pharma and biotech. It competes with L7 ESP in the lab informatics and data contextualization category, particularly for discovery and translational research customers.

TypeDirect peer
Description

LabWare is one of the largest independent LIMS providers, serving regulated pharma, biotech, and clinical labs with configurable LIMS and ELN solutions. It is a direct competitor to L7 LIMS and L7 Notebooks in the same regulated buyer accounts L7 targets.

5Sapio Sciences
TypeDirect peer
Description

Sapio Sciences provides a unified lab informatics platform combining LIMS, ELN, and scientific data management with low-code configuration, targeting biotech and clinical labs. Its unified, configurable approach directly parallels L7 ESP's integrated platform strategy.

TypeDirect peer
Description

Genedata offers an enterprise platform for biopharma R&D, covering screening, omics, biologics, and bioprocess data management. It competes with L7's workflow orchestration and data contextualization for biopharma R&D workflows.

TypeBroad incumbent
Description

Thermo Fisher offers enterprise LIMS and lab informatics software tied to its instrument portfolio, including SampleManager LIMS for regulated labs. It competes with L7 LIMS and instrument connector ecosystem in QC and regulated manufacturing.

TypeEmerging player
Description

TetraScience operates a scientific data cloud that ingests and harmonizes lab instrument data for life sciences R&D and manufacturing. It overlaps with L7's instrument connector library and data contextualization thesis, but focuses on data infrastructure rather than end-to-end workflows.

TypeBroad incumbent
Description

Veeva is a dominant cloud software provider for life sciences, spanning clinical, regulatory, quality, and commercial domains. Its Vault LIMS and quality/regulatory suites overlap with L7's platform breadth and target the same GxP-regulated enterprise buyers.

TypeEmerging player
Description

Scitara provides a Scientific Data Exchange (SDX) platform for instrument-to-enterprise data integration in labs. It overlaps with L7's instrument connector ecosystem and L7|EXCHANGE multi-party orchestration roadmap, particularly for instrument-driven workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment9 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration21 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

L7 Informatics

Life Sciences Workflow Orchestration Softwarel7informatics.com

L7 Informatics builds L7|ESP, an ontology-driven unified platform that orchestrates workflows and contextualizes data across research, development, manufacturing, and quality for regulated pharmaceutical, biotech, CDMO, diagnostics, and research customers.

What L7 Informatics does

L7 Informatics is a private life sciences software company founded in 2011 and headquartered in Austin, Texas, with 101-250 employees and $38 million in disclosed funding. It builds and sells L7|ESP, a unified digital platform that orchestrates end-to-end scientific and manufacturing workflows across research, development, manufacturing, and quality in GxP-regulated environments. The platform is built on an ontology-driven knowledge graph that contextualizes data at the point of execution, capturing full relationships between samples, materials, instruments, personnel, and outcomes rather than producing flat records. Built-in applications include L7 LIMS, L7 Notebooks (ELN), L7 MES, and L7 Scheduling, with adjacent modules for inventory, equipment management, stability, biorepository, and location management. Component modules include L7|MASTER (low-code authoring), L7|HUB (FAIR content repository with instrument connectors), L7|INTELLIGENCE (BI/analytics export to Snowflake, Tableau, Power BI), L7|SYNAPSE (agentic AI layer launched April 2026), and L7|EXCHANGE (multi-party orchestration, planned 2027).

The company operates an enterprise SaaS business model with subscription licensing on annual billing cycles, deployable via cloud, on-premises, or hybrid configurations. Pricing is quote-based and not publicly disclosed, sold through direct enterprise field sales augmented by strategic/implementation, technology, and OEM/reseller partners. Customer segments are primarily enterprise and include pharmaceutical companies, biotechs (particularly advanced therapeutics and cell/gene therapy), CDMOs, diagnostics organizations, CROs, academic and cancer research institutions, ag-bio companies, and life science tools providers. Named customers include QIAGEN, Dana-Farber Cancer Institute, The Jackson Laboratory, Cellipont Bioservices, CTMC, Cellares, GeneDx, Cibus, Alpine Bio, Gradalis, and CSI-Dx. Strategic priorities include the agentic AI layer, multi-party orchestration, and the Leica Biosystems pathology partnership (announced November 2025, commercial early 2026).

L7 Informatics firmographics

Firmographics
Name
L7 Informatics
Legal name
L7 Informatics, Inc.
Website
https://l7informatics.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
L7 Informatics builds L7|ESP, an ontology-driven unified platform that orchestrates workflows and contextualizes data across research, development, manufacturing, and quality for regulated pharmaceutical, biotech, CDMO, diagnostics, and research customers.
Ownership category
akta.pro rank

L7 Informatics industry classification

Industry
Product category
Life Sciences Workflow Orchestration Software
NAICS
Software Publishers (5132), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAI
Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Laboratory informatics software
  • Workflow orchestration software
  • GxP compliance software
  • Scientific data management
  • Manufacturing execution systems

Where L7 Informatics is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

L7 Informatics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Platform Subscription: L7 Informatics generates revenue primarily through licensing and subscription fees for its L7|ESP unified platform and associated applications (L7 LIMS, L7 MES, L7 Notebooks, L7 Scheduling). The platform is offered via cloud, on-premises, or hybrid deployment models, suggesting a recurring subscription revenue structure. Professional services for implementation, compliance, support, and training further complement the revenue model.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription licensing with cloud, on-premises, or hybrid deployment options

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

L7 Informatics product offering

Product offering

Core offering

L7 Informatics develops and sells L7|ESP (Enterprise Science Platform), a unified digital platform for regulated life sciences that contextualizes data at the point of execution and orchestrates end-to-end scientific and manufacturing workflows across research, development, manufacturing, and quality. The platform is built on an ontology-driven knowledge graph and includes built-in LIMS, ELN, MES, and Scheduling applications, with optional deployment via cloud, on-premises, or hybrid models to meet GxP compliance requirements.

Product overview

L7 Informatics offers L7|ESP®, a unified digital platform architecture for regulated life sciences that combines a core execution layer with modular components and best-of-breed applications. The platform components include L7|MASTER® for data and process modeling, L7|HUB® for content repository and FAIR data management, L7|INTELLIGENCE® for data intelligence and export to BI tools, L7|SYNAPSE™ for agentic AI capabilities, and L7|EXCHANGE™ for multi-party orchestration (estimated 2027 release). Built-in applications include L7 LIMS, L7 MES, L7 Notebooks (ELN), L7 Scheduling, L7 Inventory, L7 EM, L7 Stability, L7 Biorepository, and L7 Location—all integrated within the unified platform with workflow orchestration, ontology-driven data contextualization, and AI-actionable data.

Differentiator

Problem solved

Functional benefit

Brands

  • L7|ESP: The Enterprise Science Platform - a unified digital platform that contextualizes data at the point of execution and orchestrates workflows across research, development, manufacturing, and quality for regulated life sciences.
  • L7|MASTER
  • L7|HUB
  • L7|INTELLIGENCE
  • L7|SYNAPSE
  • L7|EXCHANGE
  • L7 LIMS
  • L7 MES
  • L7 Notebooks
  • L7 Scheduling
  • L7 UNIVERSITY

Products and services

  • L7|ESP® (Enterprise Science Platform)

Quantifiable outcome

  • Customer-reported efficiency gains of up to 80% after replacing manual or siloed processes with L7|ESP
  • +3 more outcomes

Companies that use L7 Informatics

Customer profile

Named customers14 records

Segments9 records

Ideal customer profiles6 records

L7 Informatics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration21 records

AI capability7 records

Feature10 records

L7 Informatics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Leica BiosystemscoreStrategic or Co-development Partner · 29 December 2025Leica Biosystems and L7 Informatics formed a strategic partnership to develop an AI-ready pathology platform integrating L7 Informatics' Enterprise Science Platform (L7|ESP) with Leica Biosystems' instrumentation. The collaboration addresses operational challenges in pathology laboratories including siloed data systems, rising diagnostic demands, and workforce shortages. Commercial product availability expected in early 2026. The unified platform is designed to automate workflows and enable AI-driven decision support across the entire pathology workflow from biopsy to diagnosis.
  • Strategic and Implementation PartnersminorImplementation/ SI/ Consulting PartnerL7 Informatics partners with strategic and implementation partners to help customers achieve full potential and ensure positive outcomes. These partners provide services including operations assessment, data + process architecture, implementation, compliance, and support, helping businesses achieve full potential and ensure positive outcomes with L7 ESP.
  • OEM and Reseller PartnersminorChannel Partner/ Reseller/ DistributorOEM partners leverage the power of L7 ESP to bring new digital infrastructure to their customers that unlocks the power of true data intelligence. Reseller partners extend L7's reach to new customer segments.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

L7 Informatics competitors and assessment

Company assessment

Broad incumbents

  • Dassault Systèmes BIOVIA: BIOVIA provides a broad scientific platform covering lab informatics, ELN, LIMS, and molecular modeling for regulated life sciences. Its enterprise breadth and global install base position it as a broad incumbent competing with L7 ESP across multiple workflow areas.
  • Thermo Fisher Scientific (SampleManager LIMS / Chromeleon): Thermo Fisher offers enterprise LIMS and lab informatics software tied to its instrument portfolio, including SampleManager LIMS for regulated labs. It competes with L7 LIMS and instrument connector ecosystem in QC and regulated manufacturing.
  • Veeva Systems: Veeva is a dominant cloud software provider for life sciences, spanning clinical, regulatory, quality, and commercial domains. Its Vault LIMS and quality/regulatory suites overlap with L7's platform breadth and target the same GxP-regulated enterprise buyers.

Direct peers

  • Benchling: Benchling is a cloud-native biotech R&D platform offering LIMS, ELN, and workflow orchestration for life sciences R&D. It competes most directly with L7's LIMS, ELN (Notebooks), and unified platform vision for biotech and pharma customers, with overlap in cell/gene therapy and biologics workflows.
  • Dotmatics: Dotmatics provides a scientific R&D informatics platform (LIMS, ELN, data management, decision support) for pharma and biotech. It competes with L7 ESP in the lab informatics and data contextualization category, particularly for discovery and translational research customers.
  • LabWare: LabWare is one of the largest independent LIMS providers, serving regulated pharma, biotech, and clinical labs with configurable LIMS and ELN solutions. It is a direct competitor to L7 LIMS and L7 Notebooks in the same regulated buyer accounts L7 targets.
  • Sapio Sciences: Sapio Sciences provides a unified lab informatics platform combining LIMS, ELN, and scientific data management with low-code configuration, targeting biotech and clinical labs. Its unified, configurable approach directly parallels L7 ESP's integrated platform strategy.
  • Genedata: Genedata offers an enterprise platform for biopharma R&D, covering screening, omics, biologics, and bioprocess data management. It competes with L7's workflow orchestration and data contextualization for biopharma R&D workflows.

Emerging players

  • TetraScience: TetraScience operates a scientific data cloud that ingests and harmonizes lab instrument data for life sciences R&D and manufacturing. It overlaps with L7's instrument connector library and data contextualization thesis, but focuses on data infrastructure rather than end-to-end workflows.
  • Scitara: Scitara provides a Scientific Data Exchange (SDX) platform for instrument-to-enterprise data integration in labs. It overlaps with L7's instrument connector ecosystem and L7|EXCHANGE multi-party orchestration roadmap, particularly for instrument-driven workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

L7 Informatics social profiles

Digital presence

L7 Informatics compliance and trust

Trust signal

Compliance2 records

L7 Informatics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

L7 Informatics leadership team

Management profile

Number of profiles

Profiles11 records

L7 Informatics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

L7 Informatics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about L7 Informatics

What does L7 Informatics do?

L7 Informatics develops and sells L7|ESP (Enterprise Science Platform), a unified digital platform for regulated life sciences that contextualizes data at the point of execution and orchestrates end-to-end scientific and manufacturing workflows across research, development, manufacturing, and quality. The platform is built on an ontology-driven knowledge graph and includes built-in LIMS, ELN, MES, and Scheduling applications, with optional deployment via cloud, on-premises, or hybrid models to meet GxP compliance requirements.

Is L7 Informatics a public or private company?

L7 Informatics is a private company. It is classified as venture growth investor backed and is currently operating.

When was L7 Informatics founded?

L7 Informatics was founded in 2012. It employs 101 to 250 people.

Where is L7 Informatics based?

L7 Informatics is headquartered in Austin, United States, in the North America region.

How does L7 Informatics make money?

One revenue line is on record: software Platform Subscription.

Who are L7 Informatics's main competitors?

Broad incumbents on record are Dassault Systèmes BIOVIA, Thermo Fisher Scientific (SampleManager LIMS / Chromeleon) and Veeva Systems. Direct peers are Benchling, Dotmatics, LabWare, Sapio Sciences and Genedata. Emerging players are TetraScience and Scitara.

Does L7 Informatics have an API?

Yes. L7 Informatics exposes a public API. Developer documentation is at l7informatics.com/l7synapse.

What industry is L7 Informatics in?

L7 Informatics's product category is Life Sciences Workflow Orchestration Software. Its primary akta.pro industry code is HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D), with a secondary code of HLAGAJAI, Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournESP® 2026.1, Solidifying the Premier Agentic Operating System for Precision SciencesL7 Informatics announced the general availability of L7|ESP 2026.1, a milestone release of its Agentic Operating System for Precision Sciences. The update integrates the L7|SYNAPSE AI framework to automate workflows and claims up to 100x faster evaluation performance through re-engineered computational engines. This release aims to unify scientific operations across research, manufacturing, and supply chains for regulated industries.PR NewswireL7 Informatics Unveils L7|ESP® 2026.1, Solidifying the Premier Agentic Operating System for Precision SciencesL7 Informatics announced the general availability of L7|ESP 2026.1, a milestone release that introduces the L7|SYNAPSE AI framework to its precision sciences operating system. The update features up to 100x faster evaluation performance and advanced compliance modeling for Normal Operating Ranges and Proven Acceptable Ranges. This release aims to unify scientific workflows across life sciences and related industries by layering autonomous agentic intelligence onto its existing infrastructure.BioSpaceL7 Informatics Advocates for Neuro-Symbolic AI in Regulated Life SciencesL7 Informatics advocates for neuro-symbolic AI in regulated life sciences, arguing that large language models lack understanding of validated workflows. The company promotes an active knowledge graph generated during execution, and released a white paper on the architecture.BioSpaceL7 Informatics Challenges the Notion of the “AI Governance Layer” in PharmaL7 Informatics CEO Vasu Rangadass argues that AI governance must be embedded in operational workflows, not added as a layer. He cites FDA guidance requiring risk-based credibility assessments and notes that governance depends on evidence, accountability, and control. L7's platform captures lineage and traceability as work is executed.AijournL7 Informatics Names Ray Veeraraghavan, Ph.D., Vice President of Science and AIL7 Informatics announced the appointment of Ray Veeraraghavan, Ph.D. as Vice President of Science and AI, reporting to CEO Vasu Rangadass. Veeraraghavan brings more than 24 years of experience in applied AI and machine learning in regulated life sciences, having previously led bioinformatics and data science innovation at Quest Diagnostics and architected an AI-enabled rapid whole-genome-sequencing system at Rady Children's Institute for Genomic Medicine. In his new role, he will lead scientific content strategy and drive adoption of the L7|SYNAPSE Agentic AI platform across the company's enterprise customer base.Third NewsThe Strategic Appointment of Dr. Ray Veeraraghavan at L7 Informatics to Enhance AI Integration in ScienceL7 Informatics announced the appointment of Dr. Ray Veeraraghavan as Vice President of Science and AI on July 17, 2026, to advance the deployment of its L7|SYNAPSE Agentic AI strategy for the life sciences sector. Dr. Veeraraghavan brings over 24 years of AI and machine learning experience, including previous roles at Quest Diagnostics where he managed applied AI strategies for a molecular diagnostics portfolio exceeding $2.5 billion and played a pivotal role in selecting L7's own platform. His hire underscores L7 Informatics' strategy of recruiting talent with direct platform experience to strengthen its customer value proposition.PR NewswireL7 Informatics Names Ray Veeraraghavan, Ph.D., Vice President of Science and AIL7 Informatics appointed Ray Veeraraghavan, Ph.D. as Vice President of Science and AI, effective immediately, with the executive reporting directly to CEO Vasu Rangadass. Veeraraghavan brings more than 24 years of experience applying AI and machine learning in regulated life sciences, including leading applied AI at Quest Diagnostics for a $2.5 billion molecular diagnostics portfolio and architecting an AI-enabled rapid whole-genome sequencing workflow at Rady Children's Institute for Genomic Medicine. In his new role, Veeraraghavan will build standardized scientific content and workflows to accelerate customer adoption of L7|SYNAPSE Agentic AI and advise senior leadership at strategic enterprise accounts.BioSpaceL7 Informatics Makes the Case for an Agentic Operating System as the Strategic Foundation for Regulated Process IndustriesL7 Informatics argues that regulated process industries need an agentic operating system, not point solutions, to support agentic AI. It cites up to 80% faster reporting, 75% less QA time, and $5.2 million annual savings from eliminating data silos. The company promotes its L7|ESP platform as the foundational layer.BioSpaceInside the 98 Percent: L7 Informatics on the Operational Harness That Determines Pharma’s Agentic AI OutcomesL7 Informatics argues that pharmaceutical AI pilots fail to reach production because operational infrastructure, not models, is lacking. It cites that only 1.6% of a production-grade AI system is decision logic, and 94% of AI investments yield no significant value. The company promotes its L7|ESP and L7|SYNAPSE platforms for regulated environments.